US extends ICDs (implantable cardioverter defibrillators) coverage to certain CHF (congestive heart failure) patients
This article was originally published in Clinica
Executive Summary
The US CMS has finally agreed to expand Medicare's coverage of implantable cardioverter defibrillators (ICDs) to certain patients with congestive heart failure (CHF). CMS claims its decision is likely to increase the number of beneficiaries who might qualify for the device by about one third, or 500,000 patients.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.